Galapagos NV
GLPG32.850USD
+0.400+1.23%
收盤 11/11, 16:00（美東）報價延遲15分鐘
2.16B總市值
虧損本益比TTM
關於 Galapagos NV 公司
Galapagos NV 是一家位於比利時的臨牀階段生物技術公司。該公司從事具有作用模式的小分子藥物的發現和開發。其產品線包括 3 期、2 期、1 期、臨牀前研究以及囊性纖維化、炎症和其他適應症的發現小分子和抗體項目。該公司專注於開發一系列臨牀階段療法，以增強現有的治療模式。它結合內部和外部科學，在高度未滿足需求的領域開發轉化藥物，目標是延長全球患者的生命年限並改善其生活質量。它發現哪些蛋白質與類風溼性關節炎、關節炎、炎症性腸病和纖維化等疾病有關。該公司收購了 CellPoint 和 AboundBio，以開發細胞療法，這是一種針對不同類型癌症的潛在轉化療法。
Galapagos NV簡介
公司代碼GLPG
公司名稱Galapagos NV
上市日期May 06, 2005
CEOHenry Gosebruch
員工數量704
證券類型Ordinary Share
年結日May 06
公司地址Generaal De Wittelaan L11 A3
城市MALINES (MECHELEN)
上市交易所Euronext Amsterdam
國家Belgium
郵編2800
電話3215342900
網址https://www.glpg.com/
公司代碼GLPG
上市日期May 06, 2005
CEOHenry Gosebruch
Galapagos NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Henry Gosebruch
Mr. Henry Gosebruch
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Dan Grossman
Mr. Dan Grossman
Chief Strategy Officer
Chief Strategy Officer
--
--
Mr. Srikant Ramaswami
Mr. Srikant Ramaswami
Senior Vice President and Global Head of Corporate Affairs and Investor Relations
Senior Vice President and Global Head of Corporate Affairs and Investor Relations
--
--
Mr. Neil Johnston
Mr. Neil Johnston
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
240.79M
87.35%
Europe
34.86M
12.65%
業務
地區
暫無數據
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Gilead Sciences Inc
25.35%
Tang Capital Management, LLC
6.51%
Madison Avenue Partners LP
2.85%
Prosight Capital
2.69%
Fidelity Management & Research Company LLC
2.25%
其他
60.34%
持股股東
持股股東
佔比
Gilead Sciences Inc
25.35%
Tang Capital Management, LLC
6.51%
Madison Avenue Partners LP
2.85%
Prosight Capital
2.69%
Fidelity Management & Research Company LLC
2.25%
其他
60.34%
股東類型
持股股東
佔比
Corporation
25.35%
Hedge Fund
16.04%
Investment Advisor
3.99%
Investment Advisor/Hedge Fund
2.85%
Research Firm
0.34%
Sovereign Wealth Fund
0.18%
Venture Capital
0.06%
Bank and Trust
0.03%
其他
51.16%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
184
15.18M
23.04%
-2.60M
2025Q2
174
14.68M
22.27%
-2.19M
2025Q1
179
31.47M
47.75%
+14.44M
2024Q4
185
31.50M
47.80%
+9.00M
2024Q3
191
14.15M
21.47%
-8.51M
2024Q2
205
20.48M
31.08%
-2.95M
2024Q1
212
21.04M
31.93%
-2.58M
2023Q4
223
20.26M
30.74%
-3.01M
2023Q3
221
19.52M
29.63%
-4.10M
2023Q2
254
20.05M
30.43%
-5.06M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Gilead Sciences Inc
16.71M
25.35%
+16.71M
--
Jun 30, 2025
Tang Capital Management, LLC
3.99M
6.06%
+28.31K
+0.71%
Jun 30, 2025
Madison Avenue Partners LP
1.88M
2.85%
+1.88M
--
Jun 30, 2025
Prosight Capital
1.77M
2.69%
+458.75K
+34.89%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.48M
2.25%
+800.00
+0.05%
Jun 30, 2025
EcoR1 Capital, LLC
1.04M
1.57%
+881.94K
+568.97%
Jun 30, 2025
Hudson Bay Capital Management LP
515.00K
0.78%
-50.00K
-8.85%
Jun 30, 2025
Segall Bryant & Hamill, LLC
501.08K
0.76%
-150.38K
-23.08%
Jun 30, 2025
Greenlight Capital, Inc.
482.75K
0.73%
--
--
Jun 30, 2025
Renaissance Technologies LLC
464.70K
0.71%
+133.90K
+40.48%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
ALPS Medical Breakthroughs ETF
1.36%
iShares Biotechnology ETF
0.11%
Avantis International Small Cap Equity ETF
0.1%
ActivePassive International Equity ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Avantis Responsible International Equity ETF
0.02%
Avantis International Equity ETF
0.01%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
佔比1.36%
iShares Biotechnology ETF
佔比0.11%
Avantis International Small Cap Equity ETF
佔比0.1%
ActivePassive International Equity ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
Avantis Responsible International Equity ETF
佔比0.02%
Avantis International Equity ETF
佔比0.01%
iShares Health Innovation Active ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
